Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly's 2005 marketing strategy aims to stem declining sales for the atypical antipsychotic Zyprexa, Exec. VP-Pharmaceutical Operation John Lechleiter, PhD, said

You may also be interested in...



Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects

CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.

Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects

CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.

"Black Box" Will Not Deter Off-Label Zyprexa Use In Dementia Patients, Lilly Says

The company points to the lack of indicated alternatives for treating dementia-related psychosis as one reason why psychiatrists will continue to prescribe atypical antipsychotics despite a new "black box" warning on mortality in that patient population. First quarter U.S. Zyprexa sales fell 17% compared to the same period in 2004.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel